Sector revisions Novartis AG

Equities

Real-time Estimate Cboe Europe Other stock markets 14:39:40 21/04/2026 BST			5-day change	1st Jan Change
115.95 ^CHF	-1.92%		-2.99%	+6.46%

07:08am	Swiss trade surplus at CHF 3.18 bln in March	RE
04-20	Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma	RE

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	NOVARTIS AG							21
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							24
	ABBVIE INC.							29
	ROCHE HOLDING AG							13
	ASTRAZENECA PLC							21
	MERCK & CO., INC.							27
	AMGEN INC.							30
	NOVO NORDISK A/S							22
	GILEAD SCIENCES, INC.							28
	PFIZER INC.							27
	BRISTOL-MYERS SQUIBB COMPANY							25
	SANOFI							23
	GSK PLC							20
	VERTEX PHARMACEUTICALS INCORPORATED							29
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	BAYER AG							19
	HALEON PLC							17
	Average							23
	Weighted average by Cap.							24